Evaluation of the VITEK 2 AST-N439 card for susceptibility testing of novel β-lactam/β-lactamase inhibitor combinations and colistin in carbapenem-non-susceptible gram-negative bacilli. [PDF]
Kim TY +7 more
europepmc +1 more source
Assessment of human exposures of cefepime-taniborbactam against cefepime-resistant Enterobacterales and Pseudomonas aeruginosa in a 7-day hollow fiber infection model. [PDF]
Avery LM +5 more
europepmc +1 more source
<i>Acinetobacter towneri</i> harbouring <i>bla</i> <sub>NDM-1</sub> and <i>bla</i> <sub>OXA-58</sub>: genomic characterization of the first human isolate from Brazil. [PDF]
Rodrigues DCS +6 more
europepmc +1 more source
Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5 years of surveillance prior to approval for clinical use (2019-2023). [PDF]
Sader HS +4 more
europepmc +1 more source
Cefepime failure for the treatment of cefepime-susceptible, KPC-producing <i>Escherichia coli</i> emphysematous cystitis. [PDF]
Morelan J +3 more
europepmc +1 more source
Imipenem/Relebactam Plus Aztreonam: First Reported Use in MDR <i>Klebsiella pneumoniae</i> Sternal Infection Complicated by Bacteremia. [PDF]
Pipitò L +8 more
europepmc +1 more source
IncL plasmid-mediated dissemination of OXA-48 β-lactamase and bla CTX-M-15 gene amplification identified via long-read sequencing in carbapenem-resistant Enterobacterales. [PDF]
Prasad S +7 more
europepmc +1 more source
Evaluation of expert rules for carbapenemase class identification in <i>Enterobacterales</i> isolates using the VITEK2 susceptibility testing platform. [PDF]
Eickhoff MJ +8 more
europepmc +1 more source

